Recombinant tumor necrosis factor (rTNF) inhibits erythropoiesis in vivo and in vitro. To study the mechanism of this inhibition, the effect of rTNF on highly purified human CFUerythroid (E) (mean purity 63.5%), which were generated from peripheral blood burst-forming units-erythroid (BFU-E), was compared to its effect on unpurified human marrow CFU-E (mean purity 0.21%). Although growth of colonies from marrow CFU-E was inhibited by rTNF, no significant effect on purified BFU-E-derived CFU-E colony growth was found. Removal of accessory marrow cells by soy bean agglutinin (SBA) ablated the inhibition of marrow CFU-E colonies by rTNF. Inhibition of colony growth was then restored by adding back SBA+ cells, but not by adding T lymphocytes or adherent cells. Conditioned medium prepared from bone marrow mononuclear cells stimulated by rTNF inhibited the growth of colonies from highly purified BFU-E derived CFU-E resistant to direct inhibition by rTNF.
Introduction
The anemia of chronic disease (ACD)' may be the most common anemia other than that due to hemorrhage and iron deficiency (1) . Recent attempts to elucidate the mechanism of ACD have concentrated on mediators of the inflammatory response that have been shown to inhibit erythropoiesis. These include interleukin-1 (2, 3) , gamma interferon (4), and tumor necrosis factor (TNF) (5) . Johnson and colleagues have recently described an animal model of ACD in which TNF-secreting tumors are implanted into nude mice (6) . These mice develop a hypoferremic anemia with normal iron stores, and show preferential inhibition of erythroid progenitors. In addition, in a phase I study ofrecombinant human TNF (rTNF) in cancer patients, patients at all dosage levels had a decrease in hemoglobin after a month of rTNF treatment (7) . In vivo or in vitro studies of marrow progenitors that are not highly purified however, cannot distinguish direct effects on erythroid progenitors from effects mediated by other cells or cell products.
A method has been reported from our laboratory by which CFU-erythroid (E) can be purified from peripheral blood burst-forming units-erythroid (BFU-E) (8) . 40-90% ofthe cells obtained by this method are CFU-E, and have been used to determine the growth requirements of erythroid progenitors (9) .
We have studied the effect of TNF on these highly purified BFU-E-derived CFU-E and have found that TNF does not inhibit purified CFU-E, but requires the presence of accessory marrow cells to exert its effect.
Methods
Blood and bone marrow were obtained from normal volunteers after informed consent. The studies were approved by the Vanderbilt University and Nashville Veteran's Affairs Medical Center Institutional Review Boards.
Recombinant human TNF alpha. rTNF with bioactivity 24 X 106 U/mg was generously provided by Dr. Abla Creasey, Cetus Corp., Emeryville, CA.
Purification of CFU-E from peripheral blood. This method has been reported in detail by Sawada et al. (8, 9 [8] ) were then cultured at a concentration of 3 X 105/ml in 0.9% methylcellulose (Fisher Scientific Co., Fair Lawn, NJ) with 30% FCS, 1% deionized HSA (American Red Cross Blood Services, Washington, DC), 10-4 M 2-mercaptoethanol (Eastman Kodak Co., Rochester, NY), penicillin 500 U/ml, streptomycin 40 Mg/ml, recombinant human insulin 10 U/ml (Eli Lilly and Co., Indianapolis, IN), recombinant human interleukin-3 50 U/ml (Genetics Institute, Cambridge, MA), and recombinant human erythropoietin 2 U/ml (AmGen Biologicals, Thousand Oaks, CA). 1-ml aliquots were plated in 12 well tissue culture plates (Linbro, Flow Laboratories, Inc., McLean, VA) at 370C in a high humidity 5% CO2 incubator for 7 d.
After 7 days, the cells were collected in MEM. Debris and residual adherent cells were then separated from BFU-E derived CFU-E by centrifugation through 10% BSA (Armour Pharmaceutical Co., Kankakee, IL), followed by centrifugation over FH, and adherence in plastic flasks with 20% FCS for 1 h at 370C. This process reproducibly yields a 94% viable population of day 8 peripheral blood cells 40-90% of which are BFU-E-derived CFU-E (8, 9). The remaining cells are polymorphonuclear and basophilic leukocytes (8) .
Marrow cell preparation. 6 ml of bone marrow was aspirated from the posterior iliac crest and collected into an equal volume of IMDM containing 5 U sodium heparin/ml. Marrow cells were then enriched for LDMN by separation over FH. For some studies, LDMN cells were depleted of accessory cells by incubation at a concentration of 1 X 108/ml with equal volumes of soybean agglutinin (SBA; Boehringer Mannheim Biochemicals, Indianapolis, IN) 2 mg/ml and density sqdimentation over 5% BSA (10) 
Results
The effects of rTNF on highly purified BFU-E-derived CFU-E and on LDMN marrow cells are shown in Fig. 1 . The results of three experiments with purified CFU-E were combined. The purity of CFU-E ranged from 41.7 to 86.8%. No significant inhibition of colony growth from highly purified BFU-E-derived CFU-E by rTNF was found at any concentration tested.
Although there was a downward trend at the highest concentration, this did not achieve statistical significance compared to control cells that were not exposed to rTNF (P = 0.1 1). In contrast, LDMN marrow CFU-E colony growth was significantly inhibited (P < 0.001) relative to controls and to BFU-E-derived CFU-E colony growth at all rTNF concentrations above 10-12 M. The appearance of TNF-resistant marrow CFU-E did not differ from the appearance of marrow CFU-E not exposed to TNF. Fig. 1 combines the results of three experiments with marrow cells with mean CFU-E purity 0.21%.
The effect of enrichment of human marrow CFU-E on inhibition oferythroid colony growth by rTNF is shown in Fig.  2 (Fig. 2) .
To demonstrate the effect of marrow accessory cells on BFU-E-derived CFU-E in the presence of TNF, bone marrow cells were obtained 8 CFU-E. Autologous T lymphocytes, adherent cells, and SBA+ cells were cultured with blood BFU-E-derived CFU-E with and without 10-'0 M rTNF in plasma clots. Growth of CFU-E was significantly inhibited by rTNF in the presence of SBA+ cells but not in the presence ofadherent cells or T lymphocytes (Table I) . Inhibition of BFU-E-derived CFU-E colony growth by rTNF required the presence of 50-100 SBA+ cells for each peripheral blood day 8 cell (data not shown). LDMN marrow cells were incubated for 48 h with rTNF 1010 M to produce TNFCM, while CCM was prepared by incubating LDMN marrow cells 48 h without rTNF. Highly purified BFU-E-derived CFU-E were then cultured with 10% CM to determine the effect on erythropoiesis. The results of three experiments are combined in Fig. 3 . The mean purity of CFU-E was 45.1±10.1%. CFU-E were significantly inhibited (P < 0.001) by TNFCM but not by CCM (P = 0.22).
Discussion
Erythropoiesis in vitro (5) and in vivo (6, 7) is inhibited by TNF. In order to more completely understand this inhibition, prepared from LDMN cells stimulated by 10-10 M rTNF. This concentration of rTNF was chosen because it represents a point at which inhibition of erythroid colony growth from LDMN marrow cells has reached a plateau. TNFCM inhibited colony growth from BFU-E-derived CFU-E resistant to direct inhibition by rTNF. Since the TNFCM cultures contained rTNF at a final concentration of 10-" M, we cannot rule out the possibility that TNF participates in inhibition of erythropoiesis in cooperation with some other factor that acts directly on CFU-E or possibly by sensitizing CFU-E to the effect of some other factor induced by TNF.
TNF stimulates the release of a large number of potential modulators of hematopoiesis, such as IL-1, IL-6, granulocytemacrophage colony-stimulating factor, platelet-derived growth factor (PDGF), transforming growth factor-B, prostaglandins, and leukotrienes (14) . It may also stimulate the release of gamma interferon indirectly via IL-1 (15) . These factors may stimulate (PDGF [16] ) or inhibit erythropoiesis (IL-1 [3] , transforming growth factor-B [17] ). PDGF and granulocytemacrophage colony-stimulating factor, however, do not effect the growth of BFU-E-derived CFU-E (9), so the net effect of TNF is inhibitory.
Enrichment of marrow for CFU-E by removal of SBA+ cells ablated inhibition of erythroid colony growth by rTNF. This indicates that the cell population which releases the inhibitor oferythropoiesis resides in the SBA+ marrow cell fraction. We confirmed this finding by adding SBA+ cells to the LDMN SBA-marrow cells and restoring inhibition of CFU-E growth by rTNF. BFU-E-derived CFU-E resistant to inhibition by 540 R. T. Means, E. N. Dessypris, and S. B. Krantz J, IT rTNF also showed inhibition of colony formation in the presence of autologous SBA+ marrow cells. The SBA+ cell fraction includes the majority of human marrow accessory cells, including T cells, B cells, monocytes (10) , and stromal elements, including endothelial cells (18) . Experiments in which autologous marrow cells were mixed with either LDMN SBAmarrow cells or BFU-E-derived CFU-E indicate that it is neither adherent cells (monocytes) nor T lymphocytes that mediate this effect.
In conclusion, we have provided evidence indicating that TNF does inhibit erythropoiesis, but does not exert a direct inhibitory effect on CFU-E. TNF leads to the release of a soluble factor which in turn inhibits the growth of CFU-E in vitro. The cell(s) and factor(s) that mediate inhibition of CFU-E require further studies for precise identification. While many potential mediators of ACD have been described, the means by which they exert their inhibitory effects, and the final common pathway ofACD, remain questions for continuing investigation.
